C. Carpenter

发表

Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.

Nicholas D. Adams, K. Swinger, R. Prinjha, 2019, Cancer cell.

Anti-tumor effects of RTX-240: an engineered red blood cell expressing 4-1BB ligand and interleukin-15

L. Turka, T. Wickham, Enping Hong, 2021, Cancer Immunology, Immunotherapy.

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma

S. Swann, R. Amado, A. Suttle, 2014, British Journal of Cancer.

362 First in human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (p) with antitumor activity in BRCA-deficient and sporadic ovarian cancers

Linda Z Sun, R. Wenham, G. Wilding, 2010 .

Correlation of PDL1 tumor expression and outcomes in renal cell carcinoma (RCC) patients (pts) treated with pazopanib (paz).

D. Figueroa, Yuan Liu, R. Gagnon, 2013 .

Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets.

Tony W Dean, R. Annan, A. P. Graves, 2016, Structure.

Functional interdependence of BRD4 and DOT1L in MLL leukemia

Andrew J. Bannister, P. Grandi, G. Drewes, 2016, Nature Structural &Molecular Biology.

Abstract CT014: GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in patients with NUT midline carcinoma (NMC) and other cancers

G. Shapiro, R. Prinjha, S. Piha-Paul, 2016 .

Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients

S. Swann, J. Dekker, R. Amado, 2014, British Journal of Cancer.

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma

S. Swann, R. Amado, A. Suttle, 2014, British Journal of Cancer.

Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?

R. Figlin, R. Townsend, J. Rosenberg, 2016, European journal of cancer.

Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypes

T. Severson, L. Wessels, J. Foley, 2018, Haematologica.

A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM)

J. Winter, J. Leonard, Zangdong He, 2016 .

Final results of a translational phase l study assessing a QOD schedule of the potent AKT inhibitor MK-2206 incorporating predictive, pharmacodynamic (PD), and functional imaging biomarkers.

A. Tolcher, N. Tunariu, A. Patnaik, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genome-wide association study (GWAS) of efficacy and safety endpoints in pazopanib- or sunitinib-treated patients with renal cell carcinoma (RCC).

K. King, Chun-Fang Xu, R. Figlin, 2014 .

First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc).

R. Wenham, G. Wilding, S. Kaye, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia

Peter A. Jones, Philip J. Chapman, P. Grandi, 2021, Nature Cancer.

BET inhibitor resistance emerges from leukaemia stem cells

Mark A. Dawson, Omar Abdel-Wahab, Alan F. Rubin, 2015, Nature.

A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST).

A. Tolcher, K. Papadopoulos, M. Beeram, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.

Manash S. Chatterjee, Linda Z Sun, R. Wenham, 2013, The Lancet. Oncology.

A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.

M. Pappalardi, M. T. McCabe, R. Kruger, 2015, Cancer cell.

MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers

Xiping Zhang, M. T. McCabe, R. Kruger, 2018, Oncogenesis.

The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma

S. Signoretti, T. Choueiri, J. Rosenberg, 2013, Clinical Cancer Research.

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors

G. Shapiro, R. Prinjha, I. Braña, 2019, JNCI cancer spectrum.

Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic

Tiffany F. Chen, C. L. Moore, L. Turka, 2021, Nature Communications.

Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial

S. Signoretti, T. Ho, R. Motzer, 2014, Clinical Cancer Research.

HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer

K. King, M. Nelson, Chun-Fang Xu, 2015, Clinical Cancer Research.

Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients.

N. Kaplowitz, P. Harter, T. Powles, 2015, European journal of cancer.

Correlation of PDL1 tumor expression and treatment outcomes in patients with renal cell carcinoma (RCC) receiving tyrosine kinase inhibitors: COMPARZ study analysis.

R. Motzer, T. Powles, T. Choueiri, 2014 .

Preclinical target validation using patient-derived cells

Arthur S Slutsky, J. Isaac, B. Pollock, 2015, Nature Reviews Drug Discovery.

Cell-Based Drug Discovery: Identification and Optimization of Small Molecules that Reduce c-MYC Protein Levels in Cells.

J. F. Mack, L. Lafrance, R. Rivero, 2021, Journal of medicinal chemistry.

Association of IL8 polymorphisms with overall survival in patients with renal cell carcinoma in COMPARZ (pazopanib versus sunitinib phase III study).

Chun-Fang Xu, R. Motzer, T. Choueiri, 2013 .

Pazopanib (Paz) monotherapy in Asian women who have not progressed after first-line chemotherapy for advanced ovarian, Fallopian tube, or primary peritoneal carcinoma.

M. Yen, Byoung-Gie Kim, Lihui Wei, 2013 .

Correlation of chromosome (Chr) 14 loss and 5q gain with outcomes of pazopanib treatment in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC).

J. Testa, G. Hudes, J. Pei, 2012 .